1. Oliai C, Feldman DR, Slotkin E, et al. Clinical safety and efficacy of ixotatug vedotin (TORL-1-23), a claudin 6-targeted ADC, as monotherapy in germ cell tumors (GCT). Presented at: 2026 ESMO ...
Hannah Naughton, MD, explains how de-escalating surgery and chemotherapy in breast cancer expands breast conservation and ...
The investigational folate receptor alpha (FRα)–targeted antibody-drug conjugate (ADC) sofetabart mipitecan (LY4170156) ...
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining ...
Matthew Gubens, MD, MS, explains how targeted therapies are moving into earlier-stage non–small cell lung cancer, while ...
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic ...
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy. The oral EGFR inhibitor sunvozertinib (Zegfrovy) is ...
These developments also strengthen the rationale for next-generation sequencing (NGS) in patients with early-stage disease.
The FDA has granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal ...
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET ...
New analysis reveals major gaps in US TNBC trial access, leaving rural and minority communities with fewer treatment options ...
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results